Systematic review and guide to selection of selective serotonin reuptake inhibitors

Drugs

Volumn 57, Issue 4, 1999, Pages 507-533

  Edwards, J Guy ^a,c   Anderson, Ian ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIMIGRAINE AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CITALOPRAM; CYTOCHROME P450 ISOENZYME; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLIZING ENZYME; FLUOXETINE; FLUVOXAMINE; HYPNOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT; OPIATE; PAROXETINE; PHENYTOIN; SEROTONIN 1 AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TERFENADINE; TRANQUILIZER; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MALAISE; META ANALYSIS; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRURITUS; REVIEW; SEXUAL DYSFUNCTION; SKIN MANIFESTATION; SOMNOLENCE; TREMOR; URTICARIA; VERTIGO; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032891773     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957040-00005     Document Type: Review

References (118)

1. 1. Fagius J, Osterman PO, Siden A, et al. Guillain-Barre syndrome following zimeldine treatment. S Neurol, Neurosurg Psychiatry 1985; 48: 65-9
2. 2. Edwards JG. Withdrawal of psychotropic drugs from the market: I. From thalidomide to zimeldine. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology. Vol 6. Chichesler: John Wiley, 1997: 199-214
3. 3. McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990; 39: 136-153
4. 4. Mendlewicz J. Pharmacologie profile and efficacy of venlafaxine. Int Clin Psychopharmacol 1995; 10 (Suppl. 2): 5-13
5. 5. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-58
6. 6. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53: 608-36
7. 7. Kasper S, Fuger J, Moller H-J. Comparative efficacy of antidepressants. Drugs 1992. 43 (Suppl. 2): 11-23
8. 8. Montgomery SA, Henry J, MacDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
9. 9. Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28: 1359-69
10. 10. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995; 9 (Suppl.): 163-78
11. 11. Edwards JG. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs. 1995; 4: 141-59
12. 12. Anderson I. Lessons to he learnt from meta-analyses of newer versus older antidepressants. Adv Psychiatr Treat 1997; 3: 58-63
13. 13. Edwards JG. Prevention of relapse and recurrence of depression: newer versus older antidepressants. Adv Psychiatr Treat 1997; 3: 52-7
14. 14. Henry JA. Toxicity of newer versus older antidepressants. Adv Psychiatr Treat 1997; 3: 41-5
15. 15. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120-7
16. 16. Steffens DC, Krishnan KRR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depression Anxiety 1997; 6: 10-18
17. 17. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxelme in major depression. Int Clin Psychopharmacol 1993: 8: 197-202
18. 18. Ansseau M, Gabriels A, Loyens J, et al. Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharmacol 1994: 9: 329-36
19. 19. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995: 56 (6): 229-37
20. 20. Bisserbe JC, Boyer P, Souetre E, et al. A 6-month sertraline fluoxetine comparative study in depressed outpatients: outcome and costs. Presented at the 20th Congress of the International College of Neuropsychopharmacology; 1996 Jun 23-7; Melbourne
21. 21. Bougerol T, Scotto J-C, Patris FM, et al. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest 1997; 14:77-89
22. 22. de Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87: 141-5
23. 23. Giagiano CA. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 1993; 4: 145-52
24. 24. Haffmans PMJ, Timmerman I., Hoogduin CAL, et al. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmcol 1996; 11: 157-64
25. 25. Kiev A, Feiger A. A double-blind comparison of fluvoxamin and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997; 58 (4): 146-52
26. 26. Latimer PR, Ravindran AV, Bernatchez J-P, et al. A six-month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression. Presented at the 20th Congress of the International College of Neuropsychopharmacology; 1996 Jun 23-7, Melbourne
27. 27. Linden RD, Newhouse P, Krishman KR, et al. SSRIs in the depressed elderly: a double-blind comparison of sertraline and fluoxetine in depressed geriatric patients. Presented at the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25, Miami
28. 28. Nemerolf CB, Ninan PT, Ballenger J, et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 1995; 3: 163-9
29. 29. Ontiveros A, Garcia-Barriga C. A double-blind comparative study of paroxetine and fluoxeline in out-patients with depression. Br J Clin Res 1997; 8: 23-32
30. 30. Patris M, Bouchard J-M, Bougerol T, et al. Citalopram versus fluoxeline: a double-blind, controlled, multicentre, phase 111 trial in patients with unipolar major depression treated in general practice, Int Clin Psychopharmacol 1996; 11: 129-36
31. 31. Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16: 373-8
32. 32. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (Suppl. 2): 34S-39S
33. 33. Sechter D, Troy S, Rioux P. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Presented at the 20th Congress of the International College of Neuropsychopharmacology; 1996 Jun 23-7; Melbourne
34. 34. Shrivastava RK, Shrivastava S, Overweg N. Efficacy trial: paroxetine and fluoxetine in depression. Presented at the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-7, San Francisco
35. 35. Tignol J. A double-Mind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993, 13 (Suppl. 2): 18S-22S
36. 36. Van Moffaert M, Bartholome F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 1995: 10:393-405
37. 37. Zanardi R, Franchini L, Gasperini M, et al. Double-Wind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153: 1631-3
38. 38. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994; 9: 25-29
39. 39. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando: Academic Press Inc., 1985
40. 40. Gardner MJ, Altmun DG. Statistics with confidence. London: British Medical Association, 1989
41. 41 Hamilton M. A rating scale for depression. J Neurol, Neurosurg Psychiatry 1960; 23: 56-63
42. 42. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9
43. 43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88
44. 44. Rawlins MD. Spontaneous reporting of adverse reactions. I: The data. Br J Clin Pharmacol 1988a; 26: 1-5
45. 45. Rawlins MD. Spontaneous reporting of adverse reactions. II: Uses. Br J Clin Pharmacol 1988b; 26: 7-11
46. 46. Wood SM, Coulson R. Adverse drug reactions on-line information trading (ADROIT) Pharmaceut Med 1993; 7: 203-13
47. 47. Rawlins MD, Jeffreys DB. Study of United Kingdom product licence applications containing new active substances, 1987-9. BMJ 1991; 302: 223-5
48. 48. Inman WHW, Rawson NSB, Wilton LV. Prescription-event monitoring. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. London: MTP Press, 1996: 21.3-35
49. 49. Rawson NSB, Pearce GL, Inman WHW. Prescription-event monitoring: methodology and recent progress. J Clin Epidemiol 1990; 43: 509-22
50. 50. Mann RD. Databases and drug epidemiology - the situation in the UK. Eur J Clin Res 1994a; 6: 91-104
51. 51. Mann RD. Epidemiologie systems: prescription event monitoring in the UK. Southampton Med J 1994b; 10: 12-7
52. 52. Andrew JE, Prescott P, Smith TMF, et al. Testing for adverse reactions using prescription event monitoring. Stat Med 1996; 15: 887-1002
53. 53. Mann RD, Wilton LV, Pearce GL, et al. Prescription-event monitoring (PF.M) in 1996 - a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S5-S11
54. 54. Edwards JG, Inman WHW, Pearce GL, et al. Prescription-event monitoring of 10895 patients treated with alprazolam. Br J Psychiatry 1991; 158:387-92
55. 55. Edwards JG, Inman WHW, Wilton L, et al. Prescription-event monitoring of 10401 patients treated with fluvoxamine. Br J Psychiatry 1994; 164: 387-95
56. 56. Edwards JG, Inman WHW, Wilton L, et al. Drug safely monitoring of 12692 patients treated with fluoxetine. Hum Psychopharmacol 1997; 12: 127-37
57. 57. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studios. Pharmacoepidemiol Drug Saf 1997; 6: 235-46
58. 38. Kubota K, Inman WHW. Terminology in prescription-event monitoring. Eur J Clin Pharmacol 1994; 46: 497-500
59. 59. Kubota K, Kubota N, Pearce GL, et al. Signalling drug-induced rash with 36 drugs recently marketed in the United Kingdom and studied by Prescription-Event Monitoring. Int J Clin Pharmacol Ther 1995; 33: 219-25
60. 60. Anderson IM, Tomerson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310; 1433-8
61. 61. Montgomery SA, Kasper S. Comparison of compliance between selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995; 9 Suppl. 4:33-40
62. 62. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc 1994; 69: 1069-81
63. 63. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 (Suppl. I): 1-21
64. 64. Davidson R A. Source of funding and outcome of clinical trials. J Gen Intern Med 1986; 1: 155-8
65. 65. Wager E, Herxheimer A. Peer review and the pharmaceutical industry. In: Godlee F, Jefferson T, editors. Peer review and health care, London: British Medical Association. In press
66. 66. Goldstein DJ, Hamilton SH, Masica DN, et al. Fluoxetine in medically stable, depressed geriatric patients: effect on weight. J Clin Psychopharmacol 1997; 17: 365-9
67. 67. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16-21
68. 68. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamme: new selective serotonin reuptake inhibitors. Clin Pharmacol 1992; 11: 930-57
69. 69. Baldwin DS. Psychotropic drugs and sexual dysfunction. Int Rev Psychiatry 1995; 7: 261-73
70. 70. Edwards JG. Adverse reactions to and interactions with psychotropic drugs: mechanisms, methods of assessment and medico-legal considerations. In: King DJ, editor. Seminars in clinical psychopharmacology. London: Gaskell Press, 1995: 480-513
71. 71. Baldwin DS, Thomas SC, Birtwhistle J. Effects of antidepressant drugs on sexual function. Int J Psychiatr Clin Pract 1997; 1:47-58
72. 72. Baldwin D, Johnson RN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995; 6: 315-25
73. 73. Cooper GL. The safety of fluoxetine - an update. Br J Psychiatry 1988; 15: (Suppl. 3): 77-86
74. 74. Wagner W, Zaborny BA, Gray TE. Fluvoxamine: a review of its safety profile in world-wide studies. Int Clin Psychopharmacol 1994; 9: 223-7
75. 75. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 (Suppl.): 61-6
76. 76. Doogan DP. Toleration and safety of sertraline: experience worldwide, Int Clin Psychopharmacol 1991; 6 (Suppl. 2): 47-56
77. 77. Rawlins MD. Spontaneous reporting of adverse drug reactions. Q J Med 1996; 59: 531-4
78. 78. Mediplus. The research database in primary care. London: International Medical Statistics UK & Ireland, 1997
79. 79. Committee on Safely of Medicines. Dystonia and withdrawal symptoms with paroxetine (Seroxat). Current Probl Pharmacovig 1993; 19: 1
80. 80. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms during withdrawal. Br J Clin Pharmacol 1996; 42: 757-63
81. 81. Teicher MT, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-10
82. 82. Dasgupta K. Additional cases of suicidal ideation associated with fluoxetine [letter]. Am J Psychiatry 1990; 147: 1570
83. 83. Creaney W, Murray I, Healy D. Antidepressant-induced suicidal ideation. Hum Psychopharmacol 1991; 6: 329-32
84. 84. King RA, Riddle MA, Chappell PB, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991; 30: 179-186
85. 85. Koizumi H. Fluoxetine and suicidal ideation [letter]. J Am Acad Child Adolesc Psychiatry 1991; 30: 695
86. 86. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48: 1027-32
87. 87. Masand P, Gupta S, Dewan M. Suicidal ideation relating to fluoxetine treatment [letter]. N Engl J Med 1991; 324: 420
88. 88. Spina E, Perucca E. Newer and older interactions: a comparative review of drug interactions. CNS Drugs 1994; 2: 479-97
89. 89. Nemcroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311-20
90. 90. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996a; 16: 273-85
91. 91. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996b; 16: 345-55
92. 92. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview writh emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 (Suppl. 1): 1-21
93. 93. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary, Number 35 (March 1998) London: British Medical Association & Pharmaceutical Press, 1998; 554-85
94. 94. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221-4
95. 95. Roos JC. Cardiac effects of antidepressant drugs: a comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol 1983; 15: 439S-45S
96. 96. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46: 42-4
97. 97. Upward JW, Edwards JG, Goldie A, et al. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 1988; 26: 399-402
98. 98. Edwards JG, Goldie A, Papayanni-Papasthatis S. The effect of paroxetine on the electrocardiogram. Psychopharmacology 1989; 97: 96-8
99. 99. Warrington SJ, Dan-Heeri J, Sinclair AJ. Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand 1989; 80 Suppl. 350: 42-4
100. 100. Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. J Clin Psychiatry 1990; Suppl. B: 37-9
101. 101. Grundemar L, Wohlfart B, Lagerstedt C, et al. Symptoms and signs of severe citalopram overdose [letter]. Lancet 1997; 349: 1602
102. 102. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 3 See 2: 59-67
103. 103. Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993; 21: 197-208
104. 104. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 225-53
105. 105. Goldney RD, Trowse MM, Chia MM. Direct cost saving of SSRI overdose. Med J Aust 1995; 162: 668-9
106. 106. Ostrom M, Eriksson A, Thorson J, et al. Fatal overdose with citalopram [letter]. Lancet 1996; 34: 339-40
107. 107. Brion F, Brion N, Durigon M. Fatal overdose with citalopram. [letter]. Lancet 1996; 348: 1380
108. 108. Personne M, Persson H. Sjoherg G. Citalopram toxicity [letter). Lancet 1997; 350: 518-9
109. 109. Glassman AH. Citalopram toxicity [letter]. Lancet 1997; 350: 818
110. 110. Gregor KJ, Overhage JM, Coons SJ, et al. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. ClinTher 1994; 16: 306-315
111. 111. Donoghue JM. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: a naturalistic follow up study. J Serotonin Res 1996 4: 267-70
112. 112. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
113. 113. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997 170: 257-63
114. 114. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organisation. Clin Ther 1994, 16: 715-30
115. 115. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993; 342: 658-61
116. 116. Lejoyeux M. Ades J, Mourad I, et al. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs 1996; 5:278-92
117. 117. Edwards G. Guide to management of antidepressant withdrawal. Prescriber 1998; 9: 107-9
118. 118. Haddad P. Lejoyeux M, Young A. Antidepressant discontinuation syndrome. BMJ 1998; 316: 1105-6